Short Interest in Senti Biosciences, Inc. (NASDAQ:SNTI) Grows By 76.1%

Senti Biosciences, Inc. (NASDAQ:SNTI) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 103,900 shares, a growth of 76.1% from the November 30th total of 59,000 shares. Currently, 3.6% of the shares of the company are short sold. Based on an average daily trading volume, of 2,220,000 shares, the short-interest ratio is presently 0.0 days.

Analysts Set New Price Targets

Separately, Chardan Capital reissued a “buy” rating and set a $10.00 target price on shares of Senti Biosciences in a report on Monday, December 2nd.

Senti Biosciences Trading Down 5.3 %

NASDAQ SNTI traded down $0.22 during trading on Friday, reaching $3.92. The company’s stock had a trading volume of 73,351 shares, compared to its average volume of 774,802. The firm has a 50 day moving average price of $3.45 and a 200 day moving average price of $2.89. Senti Biosciences has a 12 month low of $1.52 and a 12 month high of $16.94. The firm has a market capitalization of $17.99 million, a price-to-earnings ratio of -0.25 and a beta of 2.69.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.